Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
Purpose
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Condition
- Peanut Allergy
Eligibility
- Eligible Ages
- Between 4 Years and 65 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Subjects are eligible to be included in the trial only if all the following criteria apply: - Part 1: Male or female aged 12 through 65 years (inclusive) on the day of enrollment Part 2: Male or female aged 4 through 65 years (inclusive) on the day of enrollment Part 3: Male or female aged 4 through 65 years (inclusive) on the day of randomization - Documented clinical history of an IgE-mediated allergic reaction towards peanut- containing food - Peanut-specific serum IgE ≥ 0.7 kU/L at screening measured at central laboratory - Skin prick test to peanut ≥ 5 mm at screening - Cohorts 1-8: Experience dose-limiting symptoms at the 10 mg, 30 mg or 100 mg challenge dose of peanut protein on screening DBPCFC Cohorts 9-10: Experience dose-limiting symptoms at the 1 mg or 3 mg challenge dose of peanut protein on the screening DBPCFC Part 3: Experience dose-limiting symptoms at the 3 mg, 10 mg, 30 mg or 100 mg challenge dose of peanut protein on screening DBPCFC
Exclusion Criteria
Subjects are excluded from the trial if any of the following criteria apply: - Diagnosis or history of eosinophilic esophagitis - Uncontrolled asthma as defined by the Asthma Control Test questionnaire with a score of 19 or below at enrollment (subjects with a diagnosis of asthma only) - All subjects ≥ 5 years old with FEV1 or PEFR < 70% of predicted value at enrollment Subjects 4 years old with a history of recurrent wheeze requiring inhaled corticosteroids for 2 consecutive weeks or more within 3 months prior to enrollment - Up-dosing with any allergy immunotherapy product. Maintenance dose of any subcutaneous immunotherapy product other than peanut is allowed - History of peanut oral immunotherapy within the last 12 months prior to visit 1 - Chronic or acute oral inflammation at enrollment - History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension - Currently using any prohibited medication on the list of prohibited medication - Part 1 and 2: Allergic symptoms in reaction to the placebo part of the screening DBPCFC Part 3: Dose-limiting allergic symptoms in reaction to the placebo part of the screening DBPCFC - History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of the screening DBPCFC - Part 1 and 2: Asthma according to below criteria: - Severe asthma as per the current GINA guidelines - Uncontrolled or poorly controlled asthma as per the current GINA guidelines - Asthma that requires more than a daily dose above 800 µg of inhaled budesonide (or clinically comparable inhaled corticosteroids) - History of 2 or more systemic corticosteroid courses within 6 months of screening - Prior intubation/mechanical ventilation for asthma - Emergency room visit or hospitalization for asthma in the 12 months prior to screening - Any history of a life-threatening asthma attack - Part 3: Asthma fulfilling the below criteria: - History of 2 or more systemic corticosteroid courses within 6 months of screening - Prior intubation/mechanical ventilation for asthma - Emergency room visit or hospitalization for asthma in the 12 months prior to screening - Any history of a life-threatening asthma attack - (US only) Severe asthma as per the current GINA guidelines - (US only) Uncontrolled or poorly controlled asthma as per the current GINA guidelines - (US only) Asthma that requires more than a daily maintenance dose above 800 μg of inhaled budesonide (or clinically comparable inhaled corticosteroids)
Study Design
- Phase
- Phase 1/Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- Part 1 and 2 is sequential Part 3 is parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Masking Description
- Part 1 and 2 is open label. Part 3 is blinded.
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Part 1: Cohort 1 |
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks |
|
Experimental Part 1: Cohort 2 |
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks |
|
Experimental Part 1: Cohort 3 |
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks |
|
Experimental Part 1: Cohort 4 |
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks |
|
Experimental Part 1: Cohort 5 |
Adults and adolescents - peanut SLIT-tablet once daily for 2 weeks |
|
Experimental Part 2: Cohort 6 |
Adults - UDR with once daily peanut SLIT-tablet |
|
Experimental Part 2: Cohort 7 |
Adolescents - UDR with once daily peanut SLIT-tablet |
|
Experimental Part 2: Cohort 8 |
Children - UDR with once daily peanut SLIT-tablet |
|
Experimental Part 2: Cohort 9 |
Highly sensitized Adults/Adolescents - UDR with once daily peanut SLIT-tablet |
|
Experimental Part 2: Cohort 10 |
Highly sensitized Children - UDR with once daily peanut SLIT-tablet |
|
Experimental Part 3: Maintenance A |
UDR A + maintenance dose A |
|
Experimental Part 3: Maintenance B |
UDR B + maintenance dose B |
|
Placebo Comparator Part 3: Placebo |
Placebo UDR + placebo maintenance |
|
Recruiting Locations
Boston, Massachusetts 02114
More Details
- Status
- Recruiting
- Sponsor
- ALK-Abelló A/S
Detailed Description
This is a phase I/II, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 3 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents; part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children; part 3 will evaluate the efficacy of 2 maintenance doses of the SLIT-tablet primarily in adolescents and children; a small number of adults may also be included. Peanut SLIT tablets administered as 9 doses covering a 4000-fold increase in dose will be used in the study. In part 1, subjects will receive a peanut SLIT-tablet with one of five doses once daily for 2 weeks. In part 2, subjects will receive a series of increasing doses of the peanut SLIT-tablet, where each dose is taken once daily for 2 weeks. The entry dose for the up-dosing regimen will be determined from part 1. In part 3, subjects will be randomized into 3 treatment groups (UDR and Maintenance A, UDR and Maintenance B, Placebo UDR and Placebo). Subjects will receive a series of increasing doses of the peanut SLIT-tablet , where each dose is taken once daily for 2 weeks, followed by Maintenance A or B once daily for 24 weeks; or the corresponding Placebo. The trial will consist of up to 10 cohorts (part 1 is cohort 1-5; part 2 is cohort 6-10) and 3 treatment groups in part 3.